Steatohepatitis/Metabolic Liver Disease News

Patients with alcohol-associated cirrhosis had higher mortality following ICU discharge compared with patients with cirrhosis related to other causes, according to study results published in Mayo Clinic Proceedings.

Healio presents the following report on the top 10 hepatology peer-tested articles from 2021.

Many individuals look to the new year to follow through their resolutions such as diet and exercise and some are now attempting ‘Dry January’, to reset after a holiday full of drinking.

Pediatric nonalcoholic fatty liver disease-associated hospitalizations increased over time with higher rates among Hispanic adolescent boys, according to study results.

A low carbohydrate intervention targeting type 2 diabetes reversal and prediabetes regression may be an effective treatment method for nonalcoholic fatty liver disease, according to a speaker at The Liver Meeting Digital Experience.

Patients with nonalcoholic fatty liver disease and liver-involved fibrosis frequently had a cholestatic pattern that increased the risk for liver-related events, according to a presentation at The Liver Meeting Digital Experience.

Intensive lifestyle therapy in children and adolescents with nonalcoholic fatty liver disease led to significant weight loss and improvements in liver steatosis and fibrosis, according to study results.

Long-term exposure to ambient air pollutants may increase the risk of metabolic dysfunction-associated fatty liver disease, according to a study published in Journal of Hepatology.

The FDA granted fast track designation to CRV431, a potent cyclophilin inhibitor, for the treatment of patients with nonalcoholic steatohepatitis, according to a release from Hepion Pharmaceuticals.

Roux-en-Y gastric bypass and sleeve gastrectomy are equally effective at reducing hepatic steatosis, with an almost complete clearance of liver fat 1 year after the surgical procedures, according to data from a single-center study.